FDA approves Teva's biosimilar for neutropaenia in cancer patients - PMLiVE
Filgrastim-Teva 48 Mio E/0.8ml 5 Fertspr 0.8 ml auf Rezept kaufen | Amavita
Filgrastim -Teva®
FILGRASTIM Teva 30 mio U/0.5ml ser prê 0.5 ml - Pharmafoto
Japan approves second biosimilar G-CSF
Teva bolsters its biosimilar business through $160m Celltrion deal
Tbo-filgrastim Approved for Chemotherapy-Induced Neutropenia - MPR
GRANIX - Hematology Advisor
Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo- filgrastim, short-acting recombinant human granulocyte colony-stimulating factors | Request PDF
Biosimilar strategy for drugs treating neutropenia using MedDrive™ - Prime Therapeutics LLC
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation
GRANIX® (tbo-filgrastim) injection
Granix: Package Insert / Prescribing Information - Drugs.com
Delays in FDA approval of biosimilar G-CSF (filgrastim)
Teva receives FDA approval for filgrastim in the US